Pew Responds to White House's Drug Pricing Blueprint Information Request
Comments address administration’s questions on how federal, manufacturer programs affect spending
The Pew Charitable Trusts sent a letter July 16 to the U.S. Department of Health and Human Services, offering comments on the Trump administration’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs Request for Information (RFI).
Pew’s response to the RFI addresses the following topics:
- Federal program incentives.
- Drug pricing structures and incentives.
- Proposals to reform the Medicare Part B Competitive Acquisition Program.
- Price reporting requirements and incentive structures.
- Cost-shifting and cross-subsidization.
- Generic drug pricing and development.
- Pharmacy benefit managers and rebates.
- 340B Drug Pricing Program.
- Patient cost-sharing.
Spotlight on Mental Health
MORE FROM PEW
Explore Pew’s new and improved
Fiscal 50 interactive
Your state's stats are more accessible than ever with our new and improved Fiscal 50 interactive:
- Maps, trends, and customizable charts
- 50-state rankings
- Analysis of what it all means
- Shareable graphics and downloadable data
- Proven fiscal policy strategies
Welcome to the new Fiscal 50
Key changes include:
- State pages that help you keep track of trends in your home state and provide national and regional context.
- Interactive indicator pages with highly customizable and shareable data visualizations.
- A Budget Threads feature that offers Pew’s read on the latest state fiscal news.